Sex differences in the occurrence and reporting of adverse drug reactions in hypertension:
What are the clinical implications?

Author: Michel Burnier
Article type: Editorial
Received: November 3, 2022
Accepted: November 3, 2022
Early publication date: November 6, 2022
Sex differences in the occurrence and reporting of adverse drug reactions in hypertension: What are the clinical implications?

Short title: Gender differences in adverse effects of antihypertensive drugs

Michel Burnier¹, ²
¹Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
²Medical University of Gdansk, Gdańsk, Poland

Correspondence to:
Prof. Michel Burnier, MD, PhD,
Service of Nephrology and Hypertension,
Rue du Bugnon 17,
1011 Lausanne, Switzerland;
phone: +4179 40 929 00,
e-mail: michel.burnier@chuv.ch

Hypertension is a major cardiovascular and renal risk factor and a leading cause of premature death which affects both men and women [1]. However, blood pressure is a sexually dimorphic trait and as reviewed recently [2], there are clear sex differences in the prevalence, pathophysiology and consequences of hypertension between males and females. For example, one important difference is the interaction between blood pressure and age. Indeed, the rate of hypertension is significantly higher in males compared to age-matched females until the sixth decade but thereafter, the prevalence of hypertension increases steeply to become higher in females than in males [3]. International recommendations for the management of hypertension in adults do not differ substantially for males and females in terms of diagnosis, investigational procedures, drug therapy and follow-up [4, 5], the main exceptions being of course, pregnancy and the use of some antihypertensive drugs, such as blockers of the renin-angiotensin system, in women with a childbearing potential. Yet, one should perhaps be more sensitive to the fact that the sexual dimorphism concerns not only the prevalence and the pathophysiology of hypertension but also
the pharmacology of antihypertensive drugs and the risk of developing major blood pressure-related complications [6].

When considering the use of medications for the treatment of hypertension, there are evidence that sex-specificities modulate the pharmacological response to antihypertensive drugs. Indeed, there are well-described pharmacokinetic differences between males and females regarding the bioavailability, the distribution and the elimination of drugs. Thus, females tend to have a lower ratio of lean to fat tissue, a lower circulating plasma volume and a lower glomerular filtration rate [7]. Sex variations in the activity of several enzymes of the CYP system metabolizing antihypertensive drugs are also well documented [8]. Most of the time, these pharmacokinetic aspects are not taken into consideration for therapeutic recommendations because they are thought to have little impact on the efficacy and tolerability of antihypertensive medications. Nonetheless, they may result in higher drug exposure in females and hence may increase their susceptibility to dose-dependent adverse drug reactions. Hence, women may respond differently to the prescription of some antihypertensive medications both in terms of efficacy and development of adverse reactions.

In the present issue of the *Kardiologia Polska (Kardiol Pol, Polish Heart Journal)*, Polaczyk et al. [9] present the results of a recent survey performed among hypertensive patients hospitalized with the diagnosis of arterial hypertension and patients treated in an outpatient clinic for their hypertension. The main objective of the survey was to assess the prevalence of adverse drug reactions in women and men with arterial hypertension and comorbidities, and to assess the specific predisposing factors for adverse drug reactions by gender. The study enrolled 1000 consecutive patients (560 women and 440 men; mean age, 62.8 years) starting in 2019. In this population, cardiovascular comorbidities were more frequent among males whereas endocrine (but not diabetes) and rheumatoid diseases were more frequent among females. The survey consisted of 22 questions, covering various demographic and clinical factors which the patients filled in independently or with the help of a research team member. The main observation of the study is that the frequency of reported adverse drug-induced symptoms was significantly higher in female (54%) than in male patients (41%) despite the fact that females were taking significantly fewer drugs. Interestingly, this was true also for drug intolerance associated with the use of antibiotics or analgesics. In both genders, the reporting of adverse drug reactions increased with age mainly
due to an increased number of prescribed drugs. In males, the prescription of other cardiovascular
drugs (statins, antiplatelet agents…) contributed significantly to the increased reporting of adverse
drug reactions whereas in females the risk of developing adverse drug reactions was rather
associated with the use of respiratory drugs and to a lower degree to the use of anti-rheumatoid
drugs and antiplatelet agents.

The results of this interesting survey tend to confirm previous observations from various countries
suggesting that women are more likely to report adverse drug reactions for most common
antihypertensive drugs or to be admitted to the hospital because of a drug-induced adverse reaction
[10]. The reasons why women tend to report more adverse drug reactions or drug intolerance is
not completely understood. Whether reported events are true pharmacological reactions or only
perceived events is not always well defined and the reality is probably a mix of both. Thus, it is
interesting to note that in placebo-controlled studies up to 14% of men receiving classical
antihypertensive drugs report side effects leading to the discontinuation of the drugs and with
statins this figure may reach 25% [11, 12]. One of the possible reason for the gender difference
may be that women are less confident in the potential benefits of drugs and have a different
perception of the health risk related to their hypertension. One important issue is that the reporting
of adverse reactions or multiple drug intolerance, as observed in Polaczyk’s study [9], is an
important determinant of a poor adherence and drug withdrawal. Indeed, the report of several side
effects is often an indirect signal for patients to indicate that they are not willing to continue some
of their medications. In this respect, it is interesting to mention that observational studies have
often reported a lower level of adherence to antihypertensive medications among females than
males [13]. However, this observation remains controversial. Actually, a systematic review and
meta-analyses of 82 studies (15 517 457 men and 18 537 599 women) did not provide definitive
evidence of sex differences in adherence to antihypertensive therapy [14].

Another potential clinical consequence of a high reporting of drug-related adverse reactions might
be a poor control of blood pressure mediated by a lower adherence to antihypertensive
medications. Partial or complete non-adherence is a well-recognized factor associated with a worst
control of blood pressure and an increased risk of developing cardiovascular outcomes [15].
Unfortunately, Polaczyk et al. [9] did not provide any information on the quality of blood pressure
in men and women reporting adverse drug reactions or not. This would have been an interesting
information to evaluate the clinical impact of multiple drug intolerance or the occurrence of adverse drug reactions.

The data presented by Polaczyk et al. [9] have several clinical implications. As mentioned by the authors, the first is the need to discuss regularly with patients and in particular with women, on how they tolerate their antihypertensive medications and how they feel about it and to modify the drug prescription if necessary. In case of multiple drug intolerance, the possibility of a low adherence should be envisaged and drug adherence should be monitored if blood pressure is poorly controlled. Whenever possible, the pill burden should be reduced using single pill combinations and patients should be well informed on the side-effect profile of antihypertensive drugs before they start to take them. At last, the most effective approach is probably to dedicate more time to discuss with patients the possible barriers and beliefs that might interfere with their perception of the benefits and risks of antihypertensive medications.

**Article information**

**Conflict of interest:** None declared.

**Funding:** None.

**Open access:** This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

**REFERENCES**


